Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2025-12-25 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for insiders ahead of the announcement of unaudited quarterly financial results. It references the upcoming unaudited financial results for the quarter ending December 31, 2025, but does not contain any financial data or results itself. The document is short (1962 characters) and serves as an announcement related to regulatory compliance and insider trading restrictions rather than a financial report. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-12-25 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding an update on a US FDA inspection at the company's manufacturing facility. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure obligations for listed companies. The content is an update or intimation about the inspection outcome classified as 'No Action Indicated' (NAI). The document is short (1855 characters) and serves as an announcement of a regulatory event rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed audit information. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-12-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commercial launch of a pharmaceutical product, Poviztra®, by Emcure Pharmaceuticals. It is addressed to stock exchanges and is titled 'Press Release'. The content focuses on product details, market launch, and company information, without any financial data, regulatory filings, or report attachments. It does not contain financial statements, management discussion, or voting results. The document is a corporate announcement intended for public and investor information about a new product launch, which fits the category of a Capital/Financing Update or general corporate announcement. However, since it is specifically a press release about product launch and market access, and not about fundraising or capital structure changes, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2025-12-22 English
Allotment of Securities
Share Issue/Capital Change Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the allotment of equity shares pursuant to the exercise of Employee Stock Option Scheme (ESOP) 2013. It details the number of shares allotted, the increase in issued and paid-up share capital, and confirms that the new shares rank pari passu with existing shares. The document references Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to disclosures about share allotments and capital changes. The document is short (2335 characters) and is an announcement of a capital change rather than a full financial report or detailed filing. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-12-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 85% confidence The document is a formal letter from Emcure Pharmaceuticals Limited addressed to stock exchanges, notifying them about the schedule of an upcoming analyst/investor meeting. It references compliance with SEBI regulations and provides details of the meeting date, type, and mode. The document explicitly states that no unpublished price sensitive information will be shared. There is no financial data, report, or results disclosed, nor is there any indication of a report being attached or published. This is a typical investor meeting schedule notification, which aligns with the category of Investor Presentation (IP) as it relates to investor communications and presentations, even though the actual presentation content is not included. The document is short (2066 characters) and does not contain financial statements or detailed analysis, but it is not merely an announcement of a report publication. Therefore, the best fit is Investor Presentation (IP).
2025-12-01 English
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It details a regulatory action/inspection by the Goods & Service Tax Department at the company's offices. The document includes a description of the inspection, dates, and impact on the company, but does not contain financial statements or detailed financial data. It is a regulatory announcement about an inspection event, not a financial report or audit report. The document length is 3810 characters, which is relatively short and consistent with a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-27 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.